Implementation of legal and regulatory frameworks in the UK’s $850 million (£690 million/€798 million) CBD market is in disarray, a key stakeholder group alleges in a new white paper.
The Association for the Cannabinoid Industry (ACI) said the process for getting CBD products into the marketplace through the Food Standards Agency (FSA) has been “protracted, punctuated by U-turns and . . . undertaken without any discernible coordination between the responsible authorities.”
ACI called on officials to clear up “existing ambiguities” and act quickly to implement specific provisions into the law by April 2024.
First, the paper addresses “approved daily intake” (ADI) of CBD in light of controversial updated regulations issued in October by the Advisory Council on The Misuse of Drugs (ACMD). The Council ruled that based on the average lifetime exposure to food products containing CBD, healthy adults should limit their consumption of CBD in food or beverages to 10 milligrams per day – the equivalent of four or five drops of a 5% CBD oil.
Some industry representatives have suggested that an average dose of CBD needed to have a well-being or medical effect is between 60 and 120mg daily, noting that the approved medical-grade CBD product Epidiolex is administered to children at even higher levels.
The European Industrial Hemp Association (EIHA) has proposed a daily CBD dosage of 17.5mg to the European Food Safety Authority.
To read more, click on Hemp Today